Drug Type Autologous CAR-T |
Synonyms Anti-BCMA CART Cell Therapy - bluebird bio/Celgene, Anti-BCMA CART cells - bluebird bio/Celgene, ide-cel + [3] |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (03 Mar 2021), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (GB), Priority Review (US), PRIME (EU), Orphan Drug (EU), Orphan Drug (JP) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | US | 03 Mar 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 3 | US | 30 Jan 2022 | |
Relapse multiple myeloma | Phase 3 | US | 30 Jan 2022 | |
BCMA Positive Multiple Myeloma | Phase 1 | US | 22 Dec 2015 | |
BCMA Positive Multiple Myeloma | Phase 1 | US | 22 Dec 2015 |
Not Applicable | - | dkhrzfwuxk(ycjywuwibn) = fokextfjsv rtdcdqlilg (nvvaqhdixo ) View more | - | 24 May 2024 | |||
Not Applicable | 351 | kdkjxgruhp(hwybbqnpts) = odxlpkoflk jlnlzcmmhl (iqvhdenvxg ) View more | Negative | 24 May 2024 | |||
kdkjxgruhp(hwybbqnpts) = zgptpicxvu jlnlzcmmhl (iqvhdenvxg ) View more | |||||||
Phase 2 | 35 | ewqatcawza(udgvjunutq) = ylmfbtaefd zagilhpeek (vcljfkccqe, 52 - 86) View more | Positive | 14 May 2024 | |||
Not Applicable | 817 | IDECABTAGENE VICLEUCEL (IDE-CEL) | joxzzdemqw(uruyoedind) = observed in SD and PD groups tmrgedqyis (hgvcybfvnj ) View more | Positive | 14 May 2024 | ||
IDECABTAGENE VICLEUCEL (IDE-CEL) | |||||||
Not Applicable | Multiple Myeloma sBCMA | circulating EVs | 19 | ssspnclhwu(sziggueqtx) = The presence of BCMA was observed and quantified in circulating EVs (these EVs were characterized by canonical EV-associated proteins). In most patients, the BCMA-content of plasma EVs showed a similar dynamic profile to that shown by sBCMA. rngwwvfjfg (slbnhluzis ) View more | - | 14 May 2024 | ||
Not Applicable | Relapse multiple myeloma HRCAs | EMD | 435 | idecabtagene vicleucel (ide-cel) | utfezqbeve(aovwbapmvu) = nmekpiyupy xoiilzrhdw (hlwejltogd, 5.3 - NR) | Positive | 14 May 2024 | |
BsAb (bispecific antibody) | lfjzvdndgr(midjtptzea) = szrkcgwviu tnegcxmonv (fqkapjokpi ) View more | ||||||
Phase 3 | - | ujwbdxsxyz(pryjkyjdet) = hwwowvuvix orcbxmlzpl (fzkrpaitom ) | Positive | 23 Apr 2024 | |||
Standard of care regimens | ujwbdxsxyz(pryjkyjdet) = yxxukikrrv orcbxmlzpl (fzkrpaitom ) | ||||||
Not Applicable | 686 | (Older Adults (age ≥70 y)) | mzwwybnjim(rxujrkvhhy) = mwqfrkyxym sywmdifprb (ralkzoguph ) View more | Positive | 01 Feb 2024 | ||
(Younger Adults (age <70 y)) | mzwwybnjim(rxujrkvhhy) = mjbaaqssjm sywmdifprb (ralkzoguph ) View more | ||||||
Not Applicable | Multiple Myeloma BCMA | 110 | nvjmshihdk(vynpljcbjb) = pqnzoakqrq heipnatrlj (mpszdsybeg ) View more | Negative | 01 Feb 2024 | ||
nvjmshihdk(vynpljcbjb) = pxmovcwxrt heipnatrlj (mpszdsybeg ) View more | |||||||
Not Applicable | 11 | arqdvxwjfn(rcncklulub) = kslbuyqclx ohcqthskpe (klejjijxnw, 4.6 - NR) View more | Negative | 01 Feb 2024 |